Skip to main content
. 2018 Jul 3;45(3):579–590. doi: 10.1093/schbul/sby094

Table 1.

Demographic and Clinical Characteristics of the 11 Studies Included in the Meta-analysis

Study No. of Participants (% Female) Mean Age (SD) Diagnostic Group Dx Tool Mean Duration of Illness in Months (SD) % Receiving Antipsychotic Meds. Eyes Open/ Closed Software Tesla
HC FEP HC FEP
Alonso-Solis et al29 19 (36) 19 (26) 25.9 (4.7) 24.9 (4.7) FEP SCID 3.4 (1.9) 84% NR AFNI–FSL 3 T
Anticevic et al30 96 (55) 28 (57) 28.8 (10.5) 25 (9.7) ec-SCZ, brief PD, SFD SCID 4.27 (3.2) 43% Closed FSL 3 T
Duan et al31 62 (63) 68 (47) 35.2 (8.1) 36.3 (7.3) FE-SCZ SCID 40 (19) 94% NR SPM8 1.5 T
Fornito et al32 26 (63) 19 (26) 26.4 (9.7) 23.2 (4.3) FEP-SCZ, BD, DD, PNOS OPCRIT <1 year 53% Closed SPM8 3 T
Guo et al33 50 (54) 49 (39) 23.5 (2.5) 22.7 (4.6) FEP SCID 22.5 (6.71) Antipsychotic naïve Closed SPM8, DPARSF, REST 3 T
Li et al34 16 (56) 20 (70) 22.4 (4.4) 22.9 (8.5) FE-SCZ SCID 6.4 (13.6) Antipsychotic naïve Closed SPM8 3 T
Lui et al35 68 (54) 68 (56) 24.7 (8.8) 24.2 (8.6) FE-SCZ SCID 8.6 (14.3) Antipsychotic naïve Closed SPM2 3 T
Penner et al36 24 (50) 24 (13) 23.8 (4.3) 23.2 (4.2) ec-SCZ SCID 13.7 (10.9) 96% Closed SPM8 3 T
Zhang et al37 30 (43) 37 (54) 15.3 (1.6) 15.5 (1.8) FE-SCZ DSM-IV 16 (14.4) Antipsychotic naïve closed SPM8 3 T
Zheng et al38 30 (57) 35 (43) 15.43 (1.5) 15.5 (1.8) FE-SCZ SCID 6.6 (6.7) Antipsychotic naïve NR SPM8 3 T
Zhou et al39 17 (29) 17 (29) 25.7 (5.6) 22.9 (6) FE-SCZ DSM-IV <2 years 76% Closed SPM2 1.5 T

Note: HC, healthy controls; FEP, first-episode psychosis; Dx Tool, diagnostic tool; ec-SCZ, early course schizophrenia; brief PD, brief psychotic disorder; SFD, schizophreniform disorder; SCZ, schizophrenia; BD, bipolar disorder; DD, delusional disorder; PNOS, psychotic disorder not otherwise specified; DSM-IV, diagnostic statistical manual; SCID, Structured Clinical Interview for DSM; OPCRIT, Operational Criteria Checklist for Psychotic Illness and Affective Illness; NR, not reported.